Business Context and Reporting Period
This Form 8-K, dated August 7, 2017, reports a material definitive agreement between Galena Biopharma, Inc. ("Galena") and SELLAS Life Sciences Group Ltd ("SELLAS"). The filing details an Agreement and Plan of Merger under which SELLAS will become an indirect wholly-owned subsidiary of Galena. Upon closing, the combined entity will be named SELLAS Life Sciences Group, Inc. and will trade on the NASDAQ Capital Market under the ticker symbol "SLS".
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data for either company. Key financial terms of the transaction include:
- Ownership Structure: Post-merger, existing Galena stockholders are expected to own approximately 32.5% of the combined company, while SELLAS stockholders are expected to own approximately 67.5% (calculated on a fully-diluted basis, excluding 2,556,851 out-of-the-money Galena warrants).
- Consideration: SELLAS shareholders will receive Galena Common Stock based on an exchange ratio. SELLAS stock options and RSUs will be assumed by Galena. Cash will be paid in lieu of fractional shares.
- Debt and Liquidity: Galena holds a 9% Original Issue Discount Senior Secured Debenture with JGB (Cayman) Newton Ltd. in the original principal amount of $25,350,000, due November 10, 2018. The holder consented to the merger with specific amendments regarding prepayment and redemption limits.
- Termination Fees: The Merger Agreement provides for a termination fee of $750,000 and reimbursement of expenses up to $100,000 under specified circumstances.
Material Changes and Corporate Actions
The primary material change is the proposed merger of SELLAS into Galena. Additional corporate actions include:
- Reverse Stock Split: Galena seeks stockholder approval for a reverse stock split at a ratio of 30-for-one (or as mutually agreed).
- Board Composition: The combined company's board is expected to consist of seven members: five designated by SELLAS (including two independent directors) and two designated by Galena.
- Leadership: Angelos Stergiou, M.D., ScD h.c., current CEO of SELLAS, is expected to serve as CEO of the combined company.
- Equity Incentives: Galena stock options will remain outstanding, with an extended exercise period of one year (increased from three months) for non-board holders terminated without cause.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the transaction's completion, future operations, and clinical trial potential, which are subject to significant risks and uncertainties. Key contingencies and risks include:
- Closing Conditions: The merger is subject to customary closing conditions, including stockholder approval from both Galena and SELLAS.
- Regulatory and Clinical Risks: Risks include the ability to successfully initiate and complete clinical trials, regulatory approval processes, and the protection of intellectual property.
- Financial Risks: Uncertainty regarding the ability to project future cash utilization, the availability of sufficient resources for business objectives, and potential dilution from third-party financing or warrant exercises.
- Debt Restrictions: The Debenture holder consented to the merger but restricted Galena from prepaying the debt prior to the first anniversary of the merger consummation.
Important Facts for Investor Verification
- Verify the final exchange ratio and the exact number of shares to be issued to SELLAS shareholders in the upcoming proxy statement/prospectus (Form S-4).
- Confirm the outcome of the required stockholder votes for both Galena and SELLAS to approve the merger and the reverse stock split.
- Review the full terms of the Debenture consent, specifically the limitations on prepayment and the mechanics of the "Monthly Allowance" and redemption notices.
- Monitor the status of the 2,556,851 out-of-the-money Galena warrants excluded from the initial ownership percentage calculation and their potential impact on dilution.
- Assess the combined company's cash runway and capital requirements post-merger, as the filing notes risks related to projecting future cash utilization.